246 related articles for article (PubMed ID: 23974104)
21. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
22. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
[TBL] [Abstract][Full Text] [Related]
23. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
24. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
Schech A; Kazi A; Yu S; Shah P; Sabnis G
Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781
[TBL] [Abstract][Full Text] [Related]
25. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.
Liu P; Kumar IS; Brown S; Kannappan V; Tawari PE; Tang JZ; Jiang W; Armesilla AL; Darling JL; Wang W
Br J Cancer; 2013 Oct; 109(7):1876-85. PubMed ID: 24008666
[TBL] [Abstract][Full Text] [Related]
26. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
27. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
28. Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC.
Wu L; Meng F; Dong L; Block CJ; Mitchell AV; Wu J; Jang H; Chen W; Polin L; Yang Q; Dou QP; Wu G
Sci Rep; 2019 Jan; 9(1):236. PubMed ID: 30659204
[TBL] [Abstract][Full Text] [Related]
29. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
30. Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer.
Tian J; Hachim MY; Hachim IY; Dai M; Lo C; Raffa FA; Ali S; Lebrun JJ
Sci Rep; 2017 Jan; 7():40258. PubMed ID: 28054666
[TBL] [Abstract][Full Text] [Related]
31. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
32. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
[TBL] [Abstract][Full Text] [Related]
33. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
34. Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.
Bodenstine TM; Chandler GS; Reed DW; Margaryan NV; Gilgur A; Atkinson J; Ahmed N; Hyser M; Seftor EA; Strizzi L; Hendrix MJ
Cell Cycle; 2016 May; 15(9):1295-302. PubMed ID: 27007464
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
36. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
[No Abstract] [Full Text] [Related]
37. Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.
Ketola K; Kallioniemi O; Iljin K
PLoS One; 2012; 7(12):e51470. PubMed ID: 23251544
[TBL] [Abstract][Full Text] [Related]
38. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
39. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
40. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer.
Chen D; Ma Y; Li P; Liu M; Fang Y; Zhang J; Zhang B; Hui Y; Yin Y
Molecules; 2019 Jun; 24(12):. PubMed ID: 31242627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
